Pathstone Family Office’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pathstone Family Office’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$290K	Buy	+3,275	New	+$291K	﹤0.01%	1329
2021 Q1	–	Sell	-71	Closed	-$6K	–	746
2020 Q4	$6K	Sell	71 -150	-68%	-$11.9K	﹤0.01%	928
2020 Q3	$16K	Sell	221 -2,850	-93%	-$288K	﹤0.01%	520
2020 Q2	$379K	Hold	3,071	–	–	0.04%	122
2020 Q1	$260K	Buy	+3,071	New	+$265K	0.04%	145
2017 Q2	–	Sell	-7	Closed	-$1K	–	414
2017 Q1	$1K	Buy	+7	New	+$623	﹤0.01%	434

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pathstone Family Office's BMRN Position: Q3 2023 in Review

Pathstone Family Office opened a new position in BioMarin Pharmaceuticals (BMRN) in Q3 2023: 3,275 shares worth $290K. The stake represents ﹤0.01% of the portfolio and ranks #1329 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in BMRN as recently as Q4 2020.

Pathstone Family Office first reported a position in BMRN in Q1 2017 and has held it in 6 quarters since. The position peaked at $379K in Q2 2020. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

Pathstone Family Office held 3,275 shares of BioMarin Pharmaceuticals worth $290K as of Q3 2023.
BioMarin Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
BioMarin Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1329 holding.
Pathstone Family Office first reported a position in BioMarin Pharmaceuticals in Q1 2017 and has held it in 6 quarters since.
Pathstone Family Office's BioMarin Pharmaceuticals position peaked at $379K in Q2 2020.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.